Media inquiries:

media@zailaboratory.com

Zai Lab Launches New Tumor Treating Fields Solution in Greater China

Zai Lab (NASDAQ: ZLAB), a China and US-based innovative commercial stage biopharmaceutical company, announced the official launch of Optune® (Tumor Treating Fields or TTFields) in Greater China at a press conference held at W Hong Kong on 28th February, 2019. Greater China is the fourth market after the United States, Europe and Japan to have access to this important new medical technology. Novocure (NASDAQ: NVCR) granted Zai Lab an exclusive license to commercialize TTFields in China, Hong Kong, Macau and Taiwan.

“TTFields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and causing affected cancer cells to die. TTFields is currently marketed in the U.S., the EU and Japan for the treatment of Glioblastoma Multiforme (GBM) and in advanced clinical development for multiple solid tumor indications.” Mr William F. Doyle, Executive Chairmen of Novocure shared. GBM is a very malignant and difficult to treat brain tumor. According to statistics, 10 out of 10,000 persons are diagnosed with GBM globally, with a survival rate of only 14 to 15 months. GBM tumor cells divide quickly, creating more and more cells that form a mass, or tumor.

TTFields is a treatment for adult patients aged 22 or older. In newly diagnosed GBM cases, TTFields is primarily used after surgery and radiation with chemotherapy. It can also be used alone for treating patients with GBM that reappears after they have had chemotherapy. TTFields is a new, breakthrough non-invasive tumor treatment that differs from commonly adopted invasive cancer treatments such as chemotherapy and radiotherapy, and the first novel GBM treatment in over a decade.

Clinical studies show that the benefits of TTFields to patients with cancer recurrence are similar to chemotherapy. In another large-scale clinical trial, nearly half (43%) of patients who were treated with TTFields + chemotherapy lived for 2 years or longer, compared to patients (only 31%) treated with chemotherapy alone. It proved that using TTFields together with chemotherapy can notably extend survival time. In addition, TTFields is safely delivered to the location of a GBM tumor, and would not increase the side effects induced by chemotherapy. A video of TTFields’ application in treatment of GBM patients was played, and a Hong Kong GBM patient personally shared his TTFields experience at the press conference.

“TTFields is a new modality to cancer treatment, which has made a major breakthrough in treating GBM. We are delighted to partner with Novocure to introduce this new treatment solution to Hong Kong, and we will actively promote it in Hong Kong and the Greater China region. We hope to see the innovative TTFields treatment solution to be widely adopted in the region so that more GBM patients could benefit from the therapy. We would also like to take this opportunity to increase Hong Kong people’s awareness to this rare yet deadly brain disease, and raise public concern over brain cancer and brain-related diseases,” said Dr. Samantha Du, Founder and Chief Executive Officer of Zai Lab in her opening speech at the press conference.

Zai Lab is also working closely with Novocure to make TTFields available to patients throughout the world by helping them accelerate the development of TTFields in indications beyond GBM. In November 2018, the two companies jointly received the Deal of the Year Award at the 9th Annual BayHelix Awards Lunch Banquet held during the annual BioCentury-BayHelix China Healthcare Summit in Shanghai, China.

For event photos, speakers’ profile and Optune photos, please visit: https://www.dropbox.com/sh/cyziisfcnwg3m4j/AADgIfNqWZX03Bi9hkcrKwbca?dl=0

About Zai Lab
Founded in 2014, Zai Lab is an innovative commercial stage biopharmaceutical company focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world. The Company’s experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates targeting the fast-growing segments of China’s pharmaceutical market and global unmet medical needs. Zai Lab’s vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its partners’ and its own products in order to impact human health worldwide.

Zai Lab is headquartered in Shanghai and has offices in Beijing, Hong Kong and the US, a R&D center in Shanghai and manufacturing facilities at the Suzhou BioBay China Industry Park. Zai Lab has been listed on NASDAQ since 2017.

For media enquiry or interview arrangement, please contact:
Lea Communications
Mr. Kevin So Tel: 9162 3900 email: kevin@leaisme.com
Mr. Issac Chan Tel: 5135 5743 email: isaac@leaisme.com